Lisa Delfini - Feb 13, 2023 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role
Chief Financial Officer
Signature
/s/ Christopher Galletta, attorney-in-fact
Stock symbol
TRVI
Transactions as of
Feb 13, 2023
Transactions value $
-$6,709
Form type
4
Date filed
2/15/2023, 03:01 PM
Previous filing
Feb 15, 2022
Next filing
Feb 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRVI Common Stock Options Exercise $14.1K +27.5K +637.76% $0.51* 31.8K Feb 13, 2023 Direct F1, F2
transaction TRVI Common Stock Sale -$20.8K -8.47K -26.64% $2.45 23.3K Feb 13, 2023 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRVI Stock Option (right to buy) Options Exercise $0 -27.5K -25% $0.00 82.5K Feb 13, 2023 Common Stock 27.5K $0.51 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan.
F2 This sale represents the sale of shares necessary to meet tax withholding obligations as a result of the exercise of stock options on February 13, 2023.
F3 Includes 4,312 shares purchased through the Issuer's employee stock purchase plan.
F4 This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.